These findings indicate that the LY294002 inhibitor can interfere with the anti-ALI effect of GRg1 pretreatment, suggesting that this inhibitor may block the PI3K/ AKT signaling pathway, thus interfering with its protective effect on lung tissue. The gene discussed is AKT1; the disease is acute respiratory distress syndrome.